Showing results (571-580 of 6,290) with videos related to

Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|May 13, 2018
Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitroPeter Breining, Jonas B Jensen, Elias I Sundelin, et al.
Diabetes, Obesity & Metabolism|May 16, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trialPriscilla A Hollander, Wendy L Carofano, Raymond L H Lam, et al.
Diabetes, Obesity & Metabolism|May 17, 2018
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trialsBo Ahrén, Stephen L Atkin, Guillaume Charpentier, et al.
Diabetes, Obesity & Metabolism|May 17, 2018
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trialPhilip D Home, Raymond L H Lam, Wendy L Carofano, et al.
Diabetes, Obesity & Metabolism|July 6, 2018
Effects of the interaction between glycated haemoglobin genetic risk score and postpartum weight reduction on glycaemic changes: A gene-weight interaction analysisLiyuan Han, Donghui Duan, Shuang Zhang, et al.
Diabetes, Obesity & Metabolism|July 6, 2018
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort studyJiun-Ling Wang, Yaa-Hui Dong, Wen-Chien Ko, et al.
Diabetes, Obesity & Metabolism|July 6, 2018
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetesJulio Rosenstock, Yehuda Handelsman, Josep Vidal, et al.
Diabetes, Obesity & Metabolism|June 12, 2018
Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS)Jean Ferrières, Dominik Lautsch, Anselm K Gitt, et al.
Diabetes, Obesity & Metabolism|June 12, 2018
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE StudyPaola Fioretto, Stefano Del Prato, John B Buse, et al.
Diabetes, Obesity & Metabolism|June 13, 2018
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled studyYuya Tsurutani, Kazuki Nakai, Kosuke Inoue, et al.
Pageof 629